Navigation Links
ADVENTRX Appoints Vice President of Commercialization
Date:10/8/2007

inorelbine tartrate works by disrupting microtubule formation and is a member of the vinca alkaloid class of antineoplastic agents. Vinorelbine is indicated as a single agent or in combination with cisplatin for treatment of advanced non-small cell lung cancer and has also shown activity in breast, ovarian, and other cancers.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that preclinical and clinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical and clinical data suggests or as otherwise anticipated; the FDA's views on the appropriateness of seeking marketing approval of ANX-530 under Section 505(b)(2); difficulties or delays in developing, testing, manufacturing and marketing and obtaining regulatory approval for ANX-530, including receiving necessary regulatory approvals for clinical trials of ANX-530 and the potential for automatic injunctions regarding FDA app
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
(Date:5/21/2015)... May 21, 2015 Imagine being ... - and those of others. Being able to read ... and read people to anticipate their thoughts and actions ... emotions and feelings to create unique abstract paintings and ... games. Get inside a first-person-shooter as it creates action, ...
(Date:5/21/2015)... 20, 2015 Research and Markets ... the "2015 Global Survey on Flow Cytometry ... The primary goal of this research is ... and reagents. Key information the survey seeks to ... flow cytometers, predominantly used applications for flow cytometers, ...
(Date:5/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has ... HW_Technical Insights" report to their offering. ... in the Health and Wellness sector and has identified ... impact in the year 2015. The research service provides ... and wellness technologies that are anticipated to have the ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Global Survey on Flow Cytometry Adoption Trends 2015 2Top Technologies in the Health and Wellness Industry 2015 2
... Market Expenditures for MRSA ... $80 Million by 2012, SUNNYVALE, Calif., Jan. 29 ... issued a medical device,license for the Xpert(TM) MRSA test ... on nasal swabs and the GeneXpert(R),System. Xpert MRSA test ...
... OXFORD, England, January 29 Circassia Ltd, ... system responses,announced today that it has successfully ... second round funding. The investment,syndicate includes new ... as existing investors, including Imperial Innovations and ...
... NanoJapan, a unique, Rice University-based program that combines ... a targeted undergraduate research internship in nanotechnology, has ... prestigious Andrew Heiskell Award for Innovation in International ... to promote and honor the most outstanding initiatives ...
Cached Biology Technology:Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System 2Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System 3Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System 4Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding 2Rice wins innovation award for international program 2
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... a protein in the brain that plays a key role ... cell that supplies energy, supports cellular activity, and potentially wards ... today in the Journal of Cell Biology , may ... "Understanding the molecular machinery that helps distribute ...
... Australian and New Zealand researchers have accelerated research ... genes which will help to unravel the causes of ... findings will be published today in the prestigious journal ... of MS has remained a mystery. This discovery reveals ...
... College of Medicine have discovered how the mutated huntingtin gene ... Huntington,s disease. The report of their findings is available in ... to show that the mutated huntingtin gene activates a particular ... further, to show what effect activation of that enzyme has ...
Cached Biology News:Protein regulates movement of mitochondria in brain cells 2Protein regulates movement of mitochondria in brain cells 3Aussie and Kiwi researchers make double MS genetic discovery 2Huntington's disease deciphered 2Huntington's disease deciphered 3
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
Biology Products: